{
	"symbol": "XCLN",
	"name": "iShares Global Clean Energy Index ETF",
	"price": 28.05,
	"priceChange": 0.18,
	"percentChange": 0.645856,
	"exchangeName": "Toronto Stock Exchange",
	"exShortName": "TSX",
	"exchangeCode": "TSX",
	"marketPlace": null,
	"sector": "",
	"industry": "",
	"volume": 20,
	"openPrice": null,
	"dayHigh": null,
	"dayLow": null,
	"MarketCap": 8415000,
	"MarketCapAllClasses": 0,
	"peRatio": 30.62,
	"prevClose": 27.87,
	"dividendFrequency": "Semi-Annual",
	"dividendYield": 1.04,
	"dividendAmount": 0.201,
	"dividendCurrency": "CAD",
	"beta": 1.045588,
	"eps": null,
	"exDividendDate": "2024-06-25 00:00:00.0",
	"longDescription": "The investment objective of the Fund is to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by the index provider. The Fund currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index Under normal market conditions, the Fund will primarily invest in securities of one or more exchange-traded funds managed by BlackRock or an affiliate or international equity securities. Generally, developments in genomics (utilizing DNA to tailor medical treatments) and immunology (using the bodys immune system to fight disease) innovate the field of medicine and develop new ways to fight disease... To achieve its investment objective the Fund uses an indexing strategy.",
	"fulldescription": "The investment objective of the Fund is to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by the index provider. The Fund currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index Under normal market conditions, the Fund will primarily invest in securities of one or more exchange-traded funds managed by BlackRock or an affiliate or international equity securities. Generally, developments in genomics (utilizing DNA to tailor medical treatments) and immunology (using the bodys immune system to fight disease) innovate the field of medicine and develop new ways to fight disease... To achieve its investment objective the Fund uses an indexing strategy. Under this strategy, the Fund seeks to replicate the performance of the Index, net of expenses, by employing, directly or indirectly through investment in one or more exchange-traded funds managed by BlackRock Canada or an affiliate and/or through the use of derivatives, a replicating strategy or sampling strategy. A replicating strategy is an investment strategy intended to replicate the performance of the Index by investing, directly or indirectly, primarily in a portfolio of index securities in substantially the same proportions as they are represented in the Index. A sampling strategy is an investment strategy intended to replicate the performance of the Index by investing, directly or indirectly, primarily in a representative portfolio of securities that has an aggregate investment profile similar to the Index. The securities selected are expected to have, in the aggregate, investment characteristics, fundamen",
	"website": "www.blackrock.com/ca",
	"email": "",
	"phoneNumber": "866 474 2737",
	"fullAddress": "BCE Place, 161 Bay Street, Toronto, ON, CA",
	"employees": "",
	"shareOutStanding": 300000,
	"totalDebtToEquity": "",
	"totalSharesOutStanding": 0,
	"sharesESCROW": null,
	"vwap": null,
	"dividendPayDate": "2024-06-28",
	"weeks52high": 34.76,
	"weeks52low": 27.68,
	"alpha": -0.014086,
	"averageVolume10D": 553,
	"averageVolume20D": 496,
	"averageVolume30D": 518,
	"averageVolume50D": 442,
	"priceToBook": 2.35,
	"priceToCashFlow": 11.2,
	"returnOnEquity": 10.16,
	"returnOnAssets": 2.54,
	"day21MovingAvg": 29.083332,
	"day50MovingAvg": 30.6174,
	"day200MovingAvg": 31.339455,
	"dividend3Years": "",
	"dividend5Years": "",
	"datatype": "etf",
	"issueType": "ET",
	"close": 27.99,
	"qmdescription": "",
	"__typename": "Company"
}